Veru Stock Surges 167% After Novo Nordisk Backs Obesity Drug Trial · European Politics Markets news · PiQMarkets
4 storiesEuropean Politics & Markets
Veru Stock Surges 167% After Novo Nordisk Backs Obesity Drug Trial
window 24h
IN SHORT
Novo Nordisk has entered a clinical supply agreement with Veru Inc. for a Phase 2b trial testing enobosarm combined with Novo's obesity drug Wegovy in older adults. Novo Nordisk will provide Wegovy at no cost and secured first negotiation rights on future commercial opportunities, causing Veru's stock to surge over 167%. Meanwhile, Novo Nordisk has launched Wegovy in the UAE, its second market after the U.S., as it assesses demand for future international expansions. Strong export demand for Novo Nordisk products is also a key driver of Denmark's projected 3.7% economic growth this year, outperforming European peers.
✉Newsletter
PiQ Daily
Pick your topics. Get only what matters, on your cadence.
Key Numbers
167%Veru stock surge percentage
2countries Wegovy is launched in
3.7%projected Danish economic growth this year
Who's Involved
Novo Nordisk
pharmaceutical company supplying Wegovy for clinical trials and launching the drug
Veru Inc.
company whose drug enobosarm will be tested in combination with Wegovy
Wegovy
Novo Nordisk's obesity drug
enobosarm
Veru's drug to be tested with Wegovy
Danske Bank A/S
financial institution providing economic analysis on Denmark
Denmark
nation whose economy is boosted by Novo Nordisk exports and plans tax cuts
1 / 2
Key facts
Novo Nordisk and Veru Inc. have entered a clinical supply agreement.
The agreement is for a Phase 2b trial testing enobosarm combined with Wegovy in older adults with obesity.
Novo Nordisk will supply Wegovy at no cost for the trial.
Novo Nordisk secured first negotiation rights on future commercial opportunities with Veru.
Veru's stock price surged over 167% following the announcement.
Novo Nordisk has launched its Wegovy weight-loss pill in the UAE.
The UAE is the second country to offer Wegovy after the U.S.
Novo Nordisk will assess patient demand and healthcare infrastructure for future international launches.
Denmark's economy is projected to grow 3.7% this year.
Strong export gains, driven by Novo Nordisk products, are a key driver of Denmark's growth.
Denmark plans to reduce its corporate tax rate to boost global competitiveness.
Novo Nordisk has entered into a clinical supply agreement with Veru Inc. for an upcoming Phase 2b clinical trial. The trial will investigate the combination of Veru's drug enobosarm with Novo Nordisk's obesity treatment, Wegovy, in older adults suffering from obesity. Under the agreement, Novo Nordisk will supply Wegovy at no cost for the trial. Furthermore, Novo Nordisk has secured first negotiation rights for any future commercial opportunities arising from this collaboration, a development that led to Veru's stock price surging by over 167%.
In parallel, Novo Nordisk has officially launched its weight-loss pill, Wegovy, in the United Arab Emirates (UAE). This marks the second country where Wegovy is available, following its initial launch in the United States. The company plans to closely monitor patient demand and evaluate the healthcare infrastructure in the UAE as it considers future international market expansions for the drug. The strong performance and global demand for Novo Nordisk's products are significantly contributing to Denmark's economic outlook.
According to Danske Bank A/S, strong export gains, particularly driven by demand for Novo Nordisk A/S products, are projected to boost Denmark's economy by 3.7% this year. This growth rate is expected to outperform other European economies. In response to global economic pressures, including trade wars and high energy costs, Denmark's new center-left government is planning to reduce the corporate tax rate. This measure aims to enhance the nation's global competitiveness.
↳ Why This Matters
Novo Nordisk has entered into a clinical supply agreement with Veru Inc. for an upcoming Phase 2b clinical trial. The trial will investigate the combination of Veru's drug enobosarm with Novo Nordisk's obesity treatment, Wegovy, in older adults suffering from obesity. Under the agreement, Novo Nordisk will supply Wegovy at no cost for the trial. Furthermore, Novo Nordisk has secured first negotiation rights for any future commercial opportunities arising from this collaboration, a development that led to Veru's stock price surging by over 167%.
FREQUENTLY ASKED
Novo Nordisk will supply its weight-loss drug Wegovy at no cost for Veru's Phase 2b clinical trial testing enobosarm combined with Wegovy in older adults with obesity.
Novo Nordisk's participation and first negotiation rights on future commercial opportunities are seen as a strong signal of confidence in Veru's enobosarm-GLP-1 combination therapy.
Veru's stock surged over 167%, moving from $2.25 to a session high of $6.02, with significantly increased trading volume.
What Happens Next
01Veru will conduct and sponsor the Phase 2b PLATEAU clinical trial.
02Novo Nordisk will supply Wegovy for the duration of the trial.
03Novo Nordisk has first negotiation rights on future commercial opportunities.
Get the newsletter.
Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.
